AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT02829931 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Nivolumab
Description: Nivolumab intravenously (IV): 240 mg every (q) 3 weeks x 4 months followed by 480 mg X 4 months.
Study NCT02829931 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Bevacizumab
Description: Bevacizumab intervenously (IV): 15 mg/kg every (q) 3 weeks when given with Ipilumumab and Nivolumab combination. Dose changed to 10mg/kg every 2 weeks when given with Nivolumab only.
Study NCT02829931 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ipilimumab
Description: Ipilimumab 1mg/kg intervenously (IV) 200 mg (5 mg/mL) every (q) 3 weeks for 4 months.
Study NCT02462616 — intervention group
Intervention type: OTHER
Intervention: not intervention
Description: This is a cross-sectional study, no intervention was performed.
Study NCT04018859 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Platelet Rich Plasma Prep System
Description: intradermal injections of platelet rich plasma to the eyebrows
Study NCT04018859 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Saline
Description: intradermal injections to the eyebrows
Study NCT02546999 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: botox
Description: The agent will be given only once at point zero in the time scheme for the project.
Study NCT02546999 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo
Description: The agent will be given only once at point zero in the time scheme for the project.
Study NCT03428620 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: High Velocity Low Amplitude mobilization
Description: Mobilizations will be performed one time at each joint, prior to completing the exercise protocol during the first three treatment sessions.
Study NCT03428620 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Exercise protocol
Description: This exercise regimen is a modified version of the balance training program described by McKeon et al.
Study NCT03428620 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Exercise protocol
Description: This exercise regimen is a modified version of the balance training program described by McKeon et al.
Study NCT01130194 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Combination of treatment modalities
Description: Intravenous cyclophosphamide, rituximab, and vincristine day 1 and 8 of 28 day cycles for 6 cycles total.~Oral prednisone and procarbazine day 1-14 of every 28 day cycle. Yttrium ibritumomab tiuxetan intravenous injection. Autologous stem cell transplant with intravenous BEAM (BCNU or carmustine, etoposide, ara-C or cytarabine, melphalan) chemotherapy conditioning.
Study NCT02472275 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Antiandrogen Therapy
Description: Undergo ADT with leuprolide acetate, goserelin acetate, or degarelix
Study NCT02472275 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT02472275 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Multitargeted Tyrosine Kinase Inhibitor PLX3397
Description: Given PO
Study NCT02472275 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation Therapy
Description: Undergo radiation therapy
Study NCT04857294 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: TMJ unilateral discectomy
Description: All patients underwent general anesthesia with nasotracheal intubation, managed in most cases with intravenous anesthesia protocol, usually with remifentanil infusion. Intraoperative steroids, usually dexamethasone, were administered primarily to minimize postoperative swelling. A classic preauricular incision or a root of helix inter tragus notch incision (RHITNI) was used in most cases, as previously described. No bandage or special care was performed after the surgery. No air washing restrictions were recommended.
Study NCT01813773 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intravitreal Aflibercept Injection (IAI)
Description: EYLEA (aflibercept) is a recombinant fusion protein consisting of portions of human VEGF receptors 1 and 2 extracellular domains fused to the Fc portion of human IgG1 formulated as an iso-osmotic solution for intravitreal administration. Aflibercept is a dimeric glycoprotein with a protein molecular weight of 97 kilodaltons (kDa) and contains glycosylation, constituting an additional 15% of the total molecular mass, resulting in a total molecular weight of 115 kDa. Aflibercept is produced in recombinant Chinese hamster ovary (CHO) cells.
Study NCT03818893 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Combination of GEN0101 and Pembrolizmub
Description: New Combination immunotherapy GEN0101 and Pembrolizmub
Study NCT04183452 — intervention group
Intervention type: DRUG
Intervention: 17-Hydroxyprogesterone Caproate 250 mg IM Dose
Description: 17-Hydroxyprogesterone Caproate is a progestin indicated to reduce the risk of preterm birth in women with a singleton pregnancy who have a history of singleton spontaneous preterm birth.
Study NCT04183452 — intervention group
Intervention type: DRUG
Intervention: 17-Hydroxyprogesterone Caproate 275 mg SC Dose
Description: 17-Hydroxyprogesterone Caproate is a progestin indicated to reduce the risk of preterm birth in women with a singleton pregnancy who have a history of singleton spontaneous preterm birth
Study NCT01596933 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: BioMega SDA®
Description: Echium oil, 15ml/day, 2 times per oral 7.5ml sachet/day, during 7-week radio(chemo)therapy
Study NCT01596933 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Sunflower oil high oleic
Description: Sunflower oil high oleic, 15ml/day, 2 times per oral 7.5ml sachet/day, during 7-week radio(chemo)therapy
Study NCT03201822 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 100 mg of Cocoa Flavanols/70 kg BW
Description: Fruit-flavored non-dairy drink containing 100 cocoa flavanols/70kg BW.
Study NCT03201822 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 200 mg of Cocoa Flavanols/70 kg BW
Description: Fruit-flavored non-dairy drink containing 200 cocoa flavanols/70kg BW.
Study NCT03201822 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 400 mg of Cocoa Flavanols/70 kg BW
Description: Fruit-flavored non-dairy drink containing 400 cocoa flavanols/70kg BW.
Study NCT03201822 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: 1000 mg of Cocoa Flavanols/70 kg BW
Description: Fruit-flavored non-dairy drink containing 1000 cocoa flavanols/70kg BW.
Study NCT00996229 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Caloric restriction
Description: 20-30% CR for 6 months
Study NCT00996229 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Omega-3 (fish oil capsules)
Description: 2g/day DHA/EPA capsules for 6 months
Study NCT00996229 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Daily corn oil capsules for 6 months
Study NCT00996229 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Daily corn oil capsules for 6 months
Study NCT00996229 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Resveratrol
Description: daily resveratrol for 6 months
Study NCT00882934 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Induction to efficient treatment
Description: Informative letters.
Study NCT00882934 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Doubt to the efficacy of treatment
Description: Informative letters.
Study NCT00882934 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Induction to ineffective treatment
Description: Informative letters
Study NCT01989455 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Deferiprone
Description: Deferiprone for infusion, 10mg/mL for intravenous infusion.~Oral dose of deferiprone: 80mg/mL oral solution. (Cohort 2)
Study NCT01989455 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo: normal saline solution.
Study NCT01070940 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NG-monomethyl-L-arginine (L-NMMA)
Description: 3 mg/kg IV priming dose + 2 mg/kg/hr IV infusion for 1 hour
Study NCT01070940 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NG-monomethyl-L-arginine (L-NMMA)
Description: 6 mg/kg IV priming dose + 4 mg/kg/hr IV infusion for 1 hour
Study NCT01070940 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: NG-monomethyl-L-arginine (L-NMMA)
Description: 4.5 mg/kg IV priming dose + 3 mg/kg/hr IV infusion for 1 hour
Study NCT01070940 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Isotonic saline solution IV priming dose + IV infusion for 1 hour
Study NCT03375892 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Deep Inspiration Breath Hold during Radiation
Description: The DIBH technique involves the patient breathing to a specified threshold and then holding that level of inspiration during every radiation therapy field delivered.
Study NCT03375892 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Free breathing during radiation
Description: The patient will be instructed to breathe freely.
Study NCT00644124 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: aflibercept
Description: in combination with standard treatment R-CHOP
Study NCT00822562 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: PRFA or PMCT
Description: PRFA or PMCT 30-35W for 10-15minutes one cycle,three cycles
Study NCT00822562 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: surgery
Description: only surgery
Study NCT03257618 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temozolomide
Description: Treatment with TMZ will be given orally according to standard practices. The therapeutic schedule will be left at the investigator's discretion.~Patients will be followed every 3 months during the treatment period, at the end of the treatment with TMZ, 6 months after the end of TMZ, and then annually until tumor progression.
Study NCT03257618 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: QoL, neurocognitive and psycholpathological assessment
Description: This assessment will be performed at baseline, at 6 months, 12 months, 18 months, at the end of the treatment with TMZ, 6 months after the end of TMZ
Study NCT03345368 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: rTMS
Description: Patients will be stimulated in the dorso lateral frontal cortex. First, the motor threshold will be determined for each patient. To induce currents to the left primary sensory-motor cortex hand area (M1/S1) the coil will be placed over the scalp oriented at 45 ° from the mid-sagittal plane while subjects will sit comfortably on a chair. The coil will be systematically moved in this area until a contraction of the abductor will be identified. Motor evoked potentials (MEPs). MEPs will be registered with surface electrodes on the left hand abductor pollicis muscle using the same Magstim equipment. Then the parameters will be adjusted for the stimulation as was described before.
Study NCT03345368 — intervention group
Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham rTMS
Description: As well as the rTMS group, the motor threshold of each patient will be determined. They will experience a similar rTMS session with the difference that they not will be stimulated.
Study NCT03345368 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Diet
Description: This intervention will be applied to both groups, rTMS and sham group, as a combined therapy. The diet is low in carbohydrates, like sugary foods, pasta and bread. Instead, patients eat food with protein, natural fats and vegetables.
Study NCT03345368 — intervention group
Intervention type: OTHER
Group type: SHAM_COMPARATOR
Intervention: Diet
Description: This intervention will be applied to both groups, rTMS and sham group, as a combined therapy. The diet is low in carbohydrates, like sugary foods, pasta and bread. Instead, patients eat food with protein, natural fats and vegetables.
Study NCT02190630 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Modified Clark Twin Block
Description: The Modified Clark Twin Block is a type of functional orthodontic appliance used to posture the lower jaw forward to treat discrepancies between the upper and lower jaw bones
Study NCT00888212 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Bronchoscopy
Description: Bronchoscopy, only if no diagnosis is obtained, patients go for EUS-FNA or EBUS-TBNA, only if no diagnosis is obtained, patients go for surgical biopsy
Study NCT02653443 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Autologous apheresis Conventional untreated Platelet Components
Description: Each subject will provide two apheresis platelet donations (one per period) and receive two infusions (one per period) of autologous radiolabeled fresh platelets combined with conventional untreated platelet components stored for either 6 or 7 days (approximately 10 to 30 mL). Platelets are administered by intravenous infusion in a peripheral vein via 19-gauge butterfly infusion needle.
Study NCT02120768 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: barrier resection/1cm resection
Description: For Arm Barrier resection, if a recurrence occurs, patients would be assigned to 1cm resection for their recurrent sarcomas; For Arm 1cm resection, if a recurrence occurs, patients would be assigned to barrier resection for their recurrent sarcomas.
Study NCT02120768 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: barrier resection/1cm resection
Description: For Arm Barrier resection, if a recurrence occurs, patients would be assigned to 1cm resection for their recurrent sarcomas; For Arm 1cm resection, if a recurrence occurs, patients would be assigned to barrier resection for their recurrent sarcomas.
Study NCT02705105 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Mogamulizumab + Nivolumab
Description: i.v. administration
Study NCT04589572 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: XLIF
Description: the XLIF procedure, a minimally invasive procedure that approaches the spine from the lateral via the space between the 12th rib and the highest point of the iliac crest.
Study NCT04589572 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: PLIF
Description: open posterior lumbar interbody fusion (PLIF) or transforaminal lumbar interbody fusion (TLIF) are used to treat degenerative diseases of the spinal column.
Study NCT01738815 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Valproic Acid
Description: 500 mg orally, once daily for up to 30 days
Study NCT00428181 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Brief alcohol intervention
Description: Brief alcohol intervention
Study NCT00428181 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Brief alcohol intervention plus booster
Description: Brief alcohol intervention plus booster in a later session
Study NCT00648921 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Olanzapine Tablets 5 mg
Description: 5mg, single dose fasting
Study NCT00648921 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Zyprexa® Tablets 5 mg
Description: 5mg, single dose fasting
Study NCT02821065 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Remote Patient Monitoring
Study NCT00864175 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INCB007839
Description: 100 mg BID
Study NCT00864175 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INCB007839
Description: 200 mg BID
Study NCT00864175 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: INCB007839
Description: 300 mg BID
Study NCT00864175 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: trastuzumab
Description: trastuzumab will be administered at a loading dose of 8 mg/kg as a 90 minute intravenous infusion on Day 8. In all subsequent 21-day cycles, trastuzumab will be administered at 6 mg/kg as a 90 minute intravenous infusion on Day 1.
Study NCT00864175 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Docetaxel
Study NCT03302689 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levobupivacaine Solution
Description: TAP-block with Levobupivacaine 0,3% - 25 ml from each side
Study NCT03302689 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ropivacaine Solution
Description: TAP-block with Ropivacaine 0,3% - 25 ml from each side
Study NCT02590276 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: characterization
Study NCT03612128 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: control group
Description: Children continued their traditional physiotherapy including upper limb exercises in three times a week for 8 week.
Study NCT03612128 — intervention group
Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: intervention group
Description: Participants allocated to the experimental group completed three times a week, 8-week mirror therapy in addition to traditional physiotherapy . This protocol consisted of mirror therapy with a mirror box.
Study NCT01056653 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Standard Dose
Description: Two intevention home visits
Study NCT01056653 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: High Dose
Description: Four intervention home visits
Study NCT01056653 — intervention group
Intervention type: BEHAVIORAL
Group type: SHAM_COMPARATOR
Intervention: Comparison Group
Description: One home visit, information only
Study NCT02753868 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: exercise
Description: Participants will be asked to cycle at mild to moderate intensity for 30 minutes during either 1-st hour of 3-rd hour into treatment
Study NCT02753868 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Hemodialysis treatment
Description: Participants will receive a standard hemodialysis treatment during the study period
Study NCT02142335 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rituxan
Description: The dose of Rituxan is 375 mg/m2¬ administered as an IV infusion during weeks 1 \& 3 (days 1 \& 15)Abraxane will be administered at a fixed dose of 100 mg/m2 as an IV infusion weekly for three weeks in a row followed by one week of rest
Study NCT00299104 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: folate
Description: Intravenous repeating dose
Study NCT00299104 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: folate
Description: Intravenous repeating dose
Study NCT02671760 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SM-1
Description: 3-drug combination product containing 50 mg diphenhydramine, 5 mg zolpidem and 0.5 mg lorazepam
Study NCT01645735 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ceftaroline fosamil
Description: Ceftaroline fosamil 600 mg IV over 60 minutes q8h; treatment duration 5 to 14 days
Study NCT01645735 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Ceftriaxone plus vancomycin
Description: Ceftriaxone 2g IV over 30 minutes q24h plus vancomycin 15 mg/kg IV q12h initially and then dose adjusted based on trough concentrations; treatment duration 5 to 14 days
Study NCT03593122 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: WO2085 Moisturising Cream
Description: Week 1: 2.5 g of the investigational product WO2085 Moisturising Cream will be applied intravaginally, once daily in the evening. In addition 0.5 g (1 fingertip unit) may be applied to the outer genital area as needed (also several times per day).~Week 2-4: The frequency may be reduced by the patient as needed. In addition 0.5 g (1 fingertip unit) may be applied to the outer genital area as needed (also several times per day).
Study NCT03770208 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Intervention: Lidocaine
Description: IV Lidocaine bolus plus infusion. Weight based.
Study NCT03770208 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Control: Standard Care + Placebo
Description: Placebo IV bolus and infusion. Weight based to mimic lidocaine volume.
Study NCT02088099 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Complex clinical intervention
Description: The complex intervention in CONNECT will be tested in 3 target populations: (1) Individuals hospitalized for TBI; (2) their family members; (3) their local health care providers. All intervention components will be delivered remotely: there will be no face-to-face interaction with the research subjects. The complex intervention tested in CONNECT is comprised of the clinical direction and advice to local providers, educational, and supportive services of the Mayo Brain Rehabilitation Clinic (BRC). The specific communication modes used to interact with individual study subjects, and the specific clinical and educational support services that are provided to an individual subject by these modes, will be determined by clinical need, individual preference, and technological capacity.
Study NCT00299104 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: methotrexate
Description: Oral or parenteral repeating dose
Study NCT00299104 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methotrexate
Description: Oral or parenteral repeating dose
Study NCT00299104 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: methylprednisolone
Description: Intravenous repeating dose
Study NCT00299104 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: methylprednisolone
Description: Intravenous repeating dose